The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Multiple Myeloma Therapeutics-Global Market Insights and Sales Trends 2024
Synopsis
Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age.
The global Multiple Myeloma Therapeutics market size is expected to reach US$ 55870 million by 2029, growing at a CAGR of 10.6% from 2023 to 2029. The market is mainly driven by the significant applications of Multiple Myeloma Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Multiple Myeloma Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiation segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Multiple Myeloma Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Multiple Myeloma Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Multiple Myeloma Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Multiple Myeloma Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Multiple Myeloma Therapeutics covered in this report include Janssen Biotech, Inc., Bristol-Myers Squibb, Novartis AG, Bristol-Myers Squibb Company, Millennium Pharmaceuticals, Celgene Corporation, Kesios Therapeutics Limited, Amgene, Inc. and Genzyme Corporation, etc.
The global Multiple Myeloma Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Biotech, Inc.
Bristol-Myers Squibb
Novartis AG
Bristol-Myers Squibb Company
Millennium Pharmaceuticals
Celgene Corporation
Kesios Therapeutics Limited
Amgene, Inc.
Genzyme Corporation
Juno Therapeutics
Global Multiple Myeloma Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Multiple Myeloma Therapeutics market, Segment by Type:
Chemotherapy
Radiation
Stem Cell Transplant
Other Supportive Treatments
Global Multiple Myeloma Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Multiple Myeloma Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Multiple Myeloma (MM) is a haematological malignancy considered by the propagation of plasma cells in the bone marrow. The disease is incurable; though over the few years there have been substantial developments in therapy, determined by a greater understanding of pathophysiology. Multiple myeloma is common among men as compared to women and also arises commonly with growing age.
The global Multiple Myeloma Therapeutics market size is expected to reach US$ 55870 million by 2029, growing at a CAGR of 10.6% from 2023 to 2029. The market is mainly driven by the significant applications of Multiple Myeloma Therapeutics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Multiple Myeloma Therapeutics market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Radiation segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Multiple Myeloma Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Multiple Myeloma Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Multiple Myeloma Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Multiple Myeloma Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Multiple Myeloma Therapeutics covered in this report include Janssen Biotech, Inc., Bristol-Myers Squibb, Novartis AG, Bristol-Myers Squibb Company, Millennium Pharmaceuticals, Celgene Corporation, Kesios Therapeutics Limited, Amgene, Inc. and Genzyme Corporation, etc.
The global Multiple Myeloma Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Janssen Biotech, Inc.
Bristol-Myers Squibb
Novartis AG
Bristol-Myers Squibb Company
Millennium Pharmaceuticals
Celgene Corporation
Kesios Therapeutics Limited
Amgene, Inc.
Genzyme Corporation
Juno Therapeutics
Global Multiple Myeloma Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Multiple Myeloma Therapeutics market, Segment by Type:
Chemotherapy
Radiation
Stem Cell Transplant
Other Supportive Treatments
Global Multiple Myeloma Therapeutics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Multiple Myeloma Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Multiple Myeloma Therapeutics
1.1 Multiple Myeloma Therapeutics Market Overview
1.1.1 Multiple Myeloma Therapeutics Product Scope
1.1.2 Multiple Myeloma Therapeutics Market Status and Outlook
1.2 Global Multiple Myeloma Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Multiple Myeloma Therapeutics Market Size by Region (2018-2029)
1.4 Global Multiple Myeloma Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Multiple Myeloma Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Multiple Myeloma Therapeutics Market Size (2018-2029)
1.6.1 North America Multiple Myeloma Therapeutics Market Size (2018-2029)
1.6.2 Europe Multiple Myeloma Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Multiple Myeloma Therapeutics Market Size (2018-2029)
1.6.4 Latin America Multiple Myeloma Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Multiple Myeloma Therapeutics Market Size (2018-2029)
2 Multiple Myeloma Therapeutics Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Radiation
2.1.3 Stem Cell Transplant
2.1.4 Other Supportive Treatments
2.2 Global Multiple Myeloma Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Multiple Myeloma Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Multiple Myeloma Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Multiple Myeloma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Multiple Myeloma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Multiple Myeloma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Multiple Myeloma Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Multiple Myeloma Therapeutics Revenue Breakdown by Type (2018-2029)
3 Multiple Myeloma Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Multiple Myeloma Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Multiple Myeloma Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Multiple Myeloma Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Multiple Myeloma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Multiple Myeloma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Multiple Myeloma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Multiple Myeloma Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Multiple Myeloma Therapeutics Revenue Breakdown by Application (2018-2029)
4 Multiple Myeloma Therapeutics Competition Analysis by Players
4.1 Global Multiple Myeloma Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Multiple Myeloma Therapeutics as of 2022)
4.3 Date of Key Players Enter into Multiple Myeloma Therapeutics Market
4.4 Global Top Players Multiple Myeloma Therapeutics Headquarters and Area Served
4.5 Key Players Multiple Myeloma Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Multiple Myeloma Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Janssen Biotech, Inc.
5.1.1 Janssen Biotech, Inc. Profile
5.1.2 Janssen Biotech, Inc. Main Business
5.1.3 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Products, Services and Solutions
5.1.4 Janssen Biotech, Inc. Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Janssen Biotech, Inc. Recent Developments
5.2 Bristol-Myers Squibb
5.2.1 Bristol-Myers Squibb Profile
5.2.2 Bristol-Myers Squibb Main Business
5.2.3 Bristol-Myers Squibb Multiple Myeloma Therapeutics Products, Services and Solutions
5.2.4 Bristol-Myers Squibb Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Bristol-Myers Squibb Recent Developments
5.3 Novartis AG
5.3.1 Novartis AG Profile
5.3.2 Novartis AG Main Business
5.3.3 Novartis AG Multiple Myeloma Therapeutics Products, Services and Solutions
5.3.4 Novartis AG Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Bristol-Myers Squibb Company Recent Developments
5.4 Bristol-Myers Squibb Company
5.4.1 Bristol-Myers Squibb Company Profile
5.4.2 Bristol-Myers Squibb Company Main Business
5.4.3 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Products, Services and Solutions
5.4.4 Bristol-Myers Squibb Company Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Bristol-Myers Squibb Company Recent Developments
5.5 Millennium Pharmaceuticals
5.5.1 Millennium Pharmaceuticals Profile
5.5.2 Millennium Pharmaceuticals Main Business
5.5.3 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Products, Services and Solutions
5.5.4 Millennium Pharmaceuticals Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Millennium Pharmaceuticals Recent Developments
5.6 Celgene Corporation
5.6.1 Celgene Corporation Profile
5.6.2 Celgene Corporation Main Business
5.6.3 Celgene Corporation Multiple Myeloma Therapeutics Products, Services and Solutions
5.6.4 Celgene Corporation Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Celgene Corporation Recent Developments
5.7 Kesios Therapeutics Limited
5.7.1 Kesios Therapeutics Limited Profile
5.7.2 Kesios Therapeutics Limited Main Business
5.7.3 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Products, Services and Solutions
5.7.4 Kesios Therapeutics Limited Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Kesios Therapeutics Limited Recent Developments
5.8 Amgene, Inc.
5.8.1 Amgene, Inc. Profile
5.8.2 Amgene, Inc. Main Business
5.8.3 Amgene, Inc. Multiple Myeloma Therapeutics Products, Services and Solutions
5.8.4 Amgene, Inc. Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Amgene, Inc. Recent Developments
5.9 Genzyme Corporation
5.9.1 Genzyme Corporation Profile
5.9.2 Genzyme Corporation Main Business
5.9.3 Genzyme Corporation Multiple Myeloma Therapeutics Products, Services and Solutions
5.9.4 Genzyme Corporation Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Genzyme Corporation Recent Developments
5.10 Juno Therapeutics
5.10.1 Juno Therapeutics Profile
5.10.2 Juno Therapeutics Main Business
5.10.3 Juno Therapeutics Multiple Myeloma Therapeutics Products, Services and Solutions
5.10.4 Juno Therapeutics Multiple Myeloma Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Juno Therapeutics Recent Developments
6 North America
6.1 North America Multiple Myeloma Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Multiple Myeloma Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Multiple Myeloma Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Multiple Myeloma Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Multiple Myeloma Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Multiple Myeloma Therapeutics Market Dynamics
11.1 Multiple Myeloma Therapeutics Industry Trends
11.2 Multiple Myeloma Therapeutics Market Drivers
11.3 Multiple Myeloma Therapeutics Market Challenges
11.4 Multiple Myeloma Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
